Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1805 Target Snapshot

5-hydroxytryptamine receptor 1F · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
176Compounds
62Assays
4Approved Drugs
195.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

5-hydroxytryptamine receptor 1F shows approved-linked disease relevance led by migraine disorder. 1 more disease program remain visible in the same review block. 4 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P30939. Start with migraine disorder, then reuse UniProt P30939 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with migraine disorder, then reuse UniProt P30939 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 4 linked drugs
Open source guide
Disease program
migraine disorder

5-hydroxytryptamine receptor 1F shows approved-linked disease relevance led by migraine disorder. 1 more disease program remain visible in the same review block. 4 linked drugs remain visible in the same block.

Start review with migraine disorder because it currently carries approved-linked support. Linked drugs include ALMOTRIPTAN MALATE, ELETRIPTAN HYDROBROMIDE, LASMIDITAN, LASMIDITAN SUCCINATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 4 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 5-hydroxytryptamine receptor 1F as ChEMBL target CHEMBL1805, mapped to UniProt P30939. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
5-hydroxytryptamine receptor 1F
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1805
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P30939
5-hydroxytryptamine receptor 1F
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether 5-hydroxytryptamine receptor 1F is the right protein anchor across sources, using UniProt P30939 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why migraine disorder is currently framed as approved-linked support. It currently carries 4 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred Name5-hydroxytryptamine receptor 1F
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP30939
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Label5-hydroxytryptamine receptor 1F
UniProt AccessionP30939
Component TypeProtein
Sequence Length366 aa

5-hydroxytryptamine receptor 1F

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as 5-hydroxytryptamine receptor 1F, mapped to UniProt P30939. Sequence length is 366 aa.

Mapped IDP30939
Review name5-hydroxytryptamine receptor 1F
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

5-hydroxytryptamine receptor 1F shows approved-linked disease relevance led by migraine disorder. 1 more disease program remain visible in the same review block.

Approved-linked Approved
migraine disorder
4 linked drugs · 4 direct · 4 efficacy
Linked drugALMOTRIPTAN MALATE
Linked drugELETRIPTAN HYDROBROMIDE
Linked drugLASMIDITAN
Linked drugLASMIDITAN SUCCINATE
Clinical signal Phase I
drug dependence
1 linked drug · 1 direct · 1 efficacy
Linked drugLASMIDITAN
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with migraine disorder because it currently carries approved-linked support. Linked drugs include ALMOTRIPTAN MALATE, ELETRIPTAN HYDROBROMIDE, LASMIDITAN, LASMIDITAN SUCCINATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasemigraine disorder
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

4
Approved
1
Phase III
Assay Mix

Activity Type Distribution

IC5017.0
KI151.0
EC5027.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4851044 9.49 IC50 0.32 Preclinical
CHEMBL128636 8.8 Ki 1.6 Preclinical
CHEMBL101690 8.8 Ki 1.6 Preclinical
CHEMBL361303 8.66 Ki 2.2 Preclinical
CHEMBL3039520 8.66 Ki 2.21 Approved
CHEMBL173949 8.64 Ki 2.3 Preclinical
CHEMBL323264 8.6 Ki 2.5 Preclinical
CHEMBL606556 8.57 Ki 2.7 Preclinical
CHEMBL369705 8.54 Ki 2.9 Preclinical
CHEMBL177238 8.52 Ki 3.0 Preclinical
Distribution

pChEMBL Value Distribution

2
5.0
8
5.5
12
6.0
13
6.5
21
7.0
46
7.5
45
8.0
15
8.5
1
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

LASMIDITAN
CHEMBL3039520
Approved 2020
Properties Compare Identifier
SUMATRIPTAN
CHEMBL128
Approved 1992
Properties Compare Identifier
Assay Landscape

Assay Landscape

62
Total Assays
120
Tested Compounds
2
Assay Types
Binding — 46 assays, 120 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 30 48 7.6
cell-based format 15 14 7.0
assay format 1 58 7.8
Functional — 16 assays, 36 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 11 22 7.1
assay format 5 14 7.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine